← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Masonic Medical Research Laboratory, Inc
Utica, NY
$19,257,468
Total funding
15
Grants
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,257,468 · 15
By mechanism
R01$16,685,702 · 8
K01$1,192,723 · 2
R21$869,206 · 2
R29$246,521 · 1
R56$192,265 · 1
F32$71,051 · 1
Investigators at Masonic Medical Research Laboratory, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
From Variants to Mechanisms for Cardiac Arrhythmias$825,573
R01 · FY2023 · HL
Role of RhoA in the Molecular Pathogenesis of Heart Disease.$797,343
R01 · FY2020 · HL
Targeted inhibition of fibrosis for the prevention of heart failure$797,333
R01 · FY2018 · HL
Targeted inhibition of fibrosis for the prevention of heart failure$797,039
R01 · FY2019 · HL
Role of RhoA in the Molecular Pathogenesis of Heart Disease.$763,525
R01 · FY2019 · HL
Role of RhoA in the Molecular Pathogenesis of Heart Disease.$753,797
R01 · FY2021 · HL
Molecular and morphometric imaging of coagulation and inflammation in pulmonary embolism pathogenesis$728,651
R01 · FY2024 · HL
Molecular and morphometric imaging of coagulation and inflammation in pulmonary embolism pathogenesis$723,192
R01 · FY2025 · HL
YAP and IRF2BP2 regulation of cardiomyocyte innate immune responses$646,307
R01 · FY2023 · HL
YAP and IRF2BP2 regulation of cardiomyocyte innate immune responses$640,967
R01 · FY2022 · HL
YAP and IRF2BP2 regulation of cardiomyocyte innate immune responses$637,407
R01 · FY2025 · HL
YAP and IRF2BP2 regulation of cardiomyocyte innate immune responses$624,659
R01 · FY2024 · HL
ELECTRICAL HETEROGENEITY AND CARDIAC ARRHYTHMIAS$542,667
R01 · FY2000 · HL
MOLECULAR GENETIC BASIS FOR FAMILIAL ATRIAL FIBRILLATION$476,396
R01 · FY2004 · HL
MOLECULAR GENETIC BASIS FOR FAMILIAL ATRIAL FIBRILLATION$464,273
R01 · FY2003 · HL
MOLECULAR GENETIC BASIS FOR FAMILIAL ATRIAL FIBRILLATION$446,946
R01 · FY2002 · HL
Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill$437,500
R01 · FY2011 · HL
Mechanisms of Lipotoxic Arrhythmias$437,500
R01 · FY2021 · HL
Mechanisms of Lipotoxic Arrhythmias$437,500
R01 · FY2020 · HL
Electrical Heterogeneity and Cardiac Arrhythmias$437,500
R01 · FY2005 · HL